Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Knapke

Orthopaedic Surgery Troy, MI Medical Doctor

NPI 1366432569 CMS profile 288747

1350 Kirts Blvd, Ste 160, Troy, MI 48084

Open in the dashboard

General payments

$496,079

350 records reported · program years 2019–2025

Research payments

$1,239

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$66,378 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Donald Knapke of Troy, MI is reported in the CMS Open Payments database as having received $496,079 across 350 general payments and $1,239 in research payments paid to them. Separately, studies naming them as principal investigator received $66,378 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54,972 54
2024 General $93,334 58
2023 General $74,514 38
2022 General $57,642 18
2021 General $51,327 21
2020 General $84,817 49
2020 Research $1,239 1
2019 General $79,473 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Knapke
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Donald Knapke were reported at $54,972. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Donald Knapke Orthopaedic Surgery median Middle half National median
2019 $79,473 $644 $140–$2,844 $163
2020 $84,817 $312 $75–$1,860 $114
2021 $51,327 $520 $117–$2,495 $132
2022 $57,642 $598 $128–$2,731 $149
2023 $74,514 $461 $128–$2,264 $160
2024 $93,334 $497 $134–$2,475 $164
2025 $54,972 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MicroPort Orthopedics Inc $405,287 182 payments
  2. Zimmer Biomet Holdings, Inc. $61,150 116 payments
  3. Smith+Nephew, Inc. $25,131 29 payments
  4. Medical Device Business Services, Inc. $2,940 1 payment
  5. Stryker Corporation $575 6 payments
  6. Heraeus Medical, LLC. $241 3 payments
  7. Kyocera Medical Technologies, Inc. $238 1 payment
  8. Heron Therapeutics, Inc. $125 4 payments
  9. Medacta USA, Inc. $121 1 payment
  10. Medtronic, Inc. $91 1 payment
  11. Other $179 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $303,178 32 payments
  2. Consulting Fee $129,465 73 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,680 27 payments
  4. Travel and Lodging $25,558 86 payments
  5. Food and Beverage $9,197 132 payments
Products named General payments · program years 2019–2025
  1. MPO Medial Pivot Knee Orthopedic Product $349,066 143 payments
  2. MPO Medial Pivot Knee Knee Arthroplasty $47,600 24 payments
  3. Persona $29,696 21 payments
  4. REAL INTELLIGENCE $22,943 21 payments
  5. JOURNEY II Recon Knees $20,927 8 payments
  6. JOURNEY II Recon Knees $11,700 1 payment
  7. JOURNEY II Recon Knees $11,700 1 payment
  8. JOURNEY II XR $11,700 1 payment
  9. Persona Revision $11,305 26 payments
  10. Oxford $8,957 6 payments
  11. Other $56,940 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $1,239 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

299

Median for Orthopedic Surgery: 203

Drug cost

$2,169

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 30 $495
Meloxicam Generic 65 $482
Methocarbamol Generic 61 $387
Tramadol Hcl Generic 30 $202
Mupirocin Generic 27 $157
Omeprazole Generic 17 $111
Methylprednisolone Generic 20 $99
Oxycodone Hcl Generic 22 $99
Ibuprofen Generic 13 $91
Atorvastatin Calcium Generic 14 $45

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$487,724

Of which drugs: $14,279

Medicare patients

713

Average age 75

Services billed

3,442

460 women, 253 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Diabetes 32%
Chronic kidney disease 22%
Depression 20%
Atrial fibrillation 19%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 16 21 $11,496
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 132 728 $507

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $12
$12 — —
Prolia
  • Amgen Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record